1.Synchronous Bilateral Breast Carcinoma in a Patient with Cowden Syndrome with PTEN Mutation: A Case Report.
Sun Young KWON ; Soo Hyun YEO ; Jung Sook HA ; Sun Hee KANG
Journal of Breast Disease 2018;6(2):79-83
Cowden syndrome (CS), also known as multiple hamartomas syndrome, is a rare hereditary autosomal dominant disorder caused by a germline mutation in the phosphatase and tensin homolog (PTEN) gene mapped on chromosome 10. The clinical features of CS are variable, primarily presenting as mucocutaneous lesions (99%). A mucocutaneous lesion, such as trichilemmoma of the face or keratosis of the extremities, is an important diagnostic marker for CS. CS has been reported to increase the incidence of benign and malignant neoplasms in the breast, thyroid, and gastrointestinal tract. The risk of developing malignancy in individuals with CS is up to 10 times higher than general population throughout an entire life time.
Breast Neoplasms*
;
Breast*
;
Chromosomes, Human, Pair 10
;
Extremities
;
Gastrointestinal Tract
;
Germ-Line Mutation
;
Hamartoma
;
Hamartoma Syndrome, Multiple*
;
Humans
;
Incidence
;
Keratosis
;
Thyroid Gland
2.Primary Angiosarcoma of the Breast: A Case Report.
Ra Mi KIM ; Hunkyoung LEE ; Heebong PARK
Journal of Breast Disease 2018;6(2):73-78
Primary angiosarcoma of the breast is extremely rare and is observed in 0.0005% to 0.05% of primary breast tumor cases. The diagnosis of this tumor is difficult due to its undefined characteristics. Radiologic findings are often nonspecific and appear completely normal in one-third of patients with primary angiosarcomas. The prognosis is usually poor, and the treatment choices include mastectomy or wide excision. Radiotherapy and chemotherapy produce varying results. We report a patient with primary angiosarcoma of the breast to further our understanding of the characteristics of this tumor and facilitate the correct diagnosis of breast angiosarcoma.
Breast Neoplasms
;
Breast*
;
Diagnosis
;
Drug Therapy
;
Hemangiosarcoma*
;
Humans
;
Lymphangiosarcoma
;
Mastectomy
;
Prognosis
;
Radiotherapy
;
Sarcoma
3.Clinical Implications According to Diagnostic Methods of Human Epidermal Growth Factor Receptor 2 Positivity in Breast Cancer: A Retrospective Study.
Bong Kyun KIM ; Joon JEONG ; Wonshik HAN ; Tae In YOON ; Min Ki SEONG ; Jin Hyang JUNG ; Sung Hoo JUNG ; Jina LEE ; Woo Young SUN
Journal of Breast Disease 2018;6(2):60-72
PURPOSE: According to American Society of Clinical Oncology/College of American Pathologists guidelines, breast cancer is human epidermal growth factor receptor 2 (HER2) positive if there is HER2 protein overexpression at a 3+ level on immunohistochemistry (IHC 3+) or gene amplification (more than six copies per nucleus) on fluorescence in situ hybridization (FISH+). However, there have been few reports on whether outcomes differ based on diagnosis by these two techniques. In this study, we compared outcomes based on the two methods in patients with HER2-positive breast cancer. METHODS: This study was a retrospective analysis of HER2-positive breast cancer in 18,304 patients, including 14,652 IHC 3+ patients and 3,652 FISH+ patients from the Korean Breast Cancer Society Registry. We compared breast cancer-specific survival and overall survival based on IHC 3+ and FISH+ status with or without trastuzumab. RESULTS: Breast cancer-specific survival was significantly different between the IHC 3+ and FISH+ groups, with 5-year cumulative survival rates of 95.0% for IHC 3+ and 98.5% for FISH+ patients who did not receive trastuzumab (p=0.001) in Kaplan-Meier methods. However, there were no significant differences in breast cancer-specific survival and overall survival between IHC 3+ and FISH+ groups regardless of trastuzumab treatment in Cox proportional hazards models. CONCLUSION: The survival outcomes were not affected by the different two diagnostic methods of HER2-positive breast cancer. Further research to evaluate differences in prognosis and other characteristics according to the diagnostic methods of HER2 positivity is needed in the future.
Breast Neoplasms*
;
Breast*
;
Diagnosis
;
Epidermal Growth Factor*
;
Fluorescence
;
Gene Amplification
;
Humans*
;
Immunohistochemistry
;
In Situ Hybridization
;
Methods*
;
Prognosis
;
Proportional Hazards Models
;
Receptor, Epidermal Growth Factor*
;
Receptor, ErbB-2
;
Retrospective Studies*
;
Survival Rate
;
Trastuzumab
4.Predicting Successful Conservative Surgery after Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer.
Chang Seok KO ; Kyu Min KIM ; Jong Won LEE ; Han Shin LEE ; Sae Byul LEE ; Guiyun SOHN ; Jisun KIM ; Hee Jeong KIM ; Il Yong CHUNG ; Beom Seok KO ; Byung Ho SON ; Seung Do AHN ; Sung Bae KIM ; Hak Hee KIM ; Sei Hyun AHN
Journal of Breast Disease 2018;6(2):52-59
PURPOSE: This study aimed to determine whether clinicopathological factors are potentially associated with successful breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC) and develop a nomogram for predicting successful BCS candidates, focusing on those who are diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative tumors during the pre-NAC period. METHODS: The training cohort included 239 patients with an HR-positive, HER2-negative tumor (≥3 cm), and all of these patients had received NAC. Patients were excluded if they met any of the following criteria: diffuse, suspicious, malignant microcalcification (extent >4 cm); multicentric or multifocal breast cancer; inflammatory breast cancer; distant metastases at the time of diagnosis; excisional biopsy prior to NAC; and bilateral breast cancer. Multivariate logistic regression analysis was conducted to evaluate the possible predictors of BCS eligibility after NAC, and the regression model was used to develop the predicting nomogram. This nomogram was built using the training cohort (n=239) and was later validated with an independent validation cohort (n=123). RESULTS: Small tumor size (p < 0.001) at initial diagnosis, long distance from the nipple (p=0.002), high body mass index (p=0.001), and weak positivity for progesterone receptor (p=0.037) were found to be four independent predictors of an increased probability of BCS after NAC; further, these variables were used as covariates in developing the nomogram. For the training and validation cohorts, the areas under the receiver operating characteristic curve were 0.833 and 0.786, respectively; these values demonstrate the potential predictive power of this nomogram. CONCLUSION: This study established a new nomogram to predict successful BCS in patients with HR-positive, HER2-negative breast cancer. Given that chemotherapy is an option with unreliable outcomes for this subtype, this nomogram may be used to select patients for NAC followed by successful BCS.
Biopsy
;
Body Mass Index
;
Breast Neoplasms*
;
Breast*
;
Cohort Studies
;
Diagnosis
;
Drug Therapy*
;
Humans
;
Inflammatory Breast Neoplasms
;
Logistic Models
;
Mastectomy, Segmental
;
Neoadjuvant Therapy
;
Neoplasm Metastasis
;
Nipples
;
Nomograms
;
Receptor, Epidermal Growth Factor
;
Receptors, Progesterone
;
ROC Curve
5.Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer.
Sang Hee KIM ; Jihye CHOI ; Chan Sub PARK ; Hyun Ah KIM ; Woo Chul NOH ; Min Ki SEONG
Journal of Breast Disease 2018;6(2):46-51
PURPOSE: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. METHODS: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. RESULTS: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. CONCLUSION: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.
Aromatase Inhibitors
;
Aromatase*
;
Breast Neoplasms*
;
Breast*
;
Follow-Up Studies
;
Gonadotropin-Releasing Hormone*
;
Goserelin
;
Humans
;
Lutein*
;
Medical Records
;
Premenopause
;
Retrospective Studies
6.Apoptosis and Cell Cycle Arrest in Two Human Breast Cancer Cell Lines by Dieckol Isolated from Ecklonia cava.
Sun Hyong YOU ; Jeong Soo KIM ; Yong Seok KIM
Journal of Breast Disease 2018;6(2):39-45
PURPOSE: Dieckol, a phlorotannin compound isolated from Ecklonia cava, has been reported to have antioxidant, antiviral, anti-inflammatory, and anticancer properties. The purpose of this study was to investigate its anticancer effects on human breast cancer cell lines. METHODS: In this study, the viability of two human breast cancer cell lines SK-BR-3 and MCF-7 was investigated after dieckol treatment using a WST-1 assay. Apoptosis and cell cycle distribution were assayed via Annexin V-fluorescein isothiocyanate and propidium iodide staining followed by flow cytometric analysis. Immunoblotting analysis was also performed using Bax/Bcl-2 to determine whether the dieckol-induced apoptosis was mediated by the intrinsic apoptotic pathway. RESULTS: In a dose dependent manner, dieckol reduced the number of viable cells and increased the number of apoptotic cells. The effect of dieckol on the cell cycle distribution was analyzed using flow cytometry. Dieckol treatment significantly increased the percentage of MCF-7 and SK-BR-3 in the G2/M phase. Immunoblot analysis revealed that 24 hours of dieckol exposure increased the Bax/Bcl-2 ratio. CONCLUSION: Dieckol induced cytotoxicity in MCF-7 and SK-BR-3 human breast cancer cells inducing apoptosis and cell cycle arrest. Therefore, it is suggested that dieckol may be a potential therapeutic agent for breast cancer.
Apoptosis*
;
Breast Neoplasms*
;
Breast*
;
Cell Cycle Checkpoints*
;
Cell Cycle*
;
Cell Line*
;
Flow Cytometry
;
Humans*
;
Immunoblotting
;
Propidium
7.Development of an Excel Program for the Updated Eighth American Joint Committee on Cancer Breast Cancer Staging System.
Jaewon JO ; Eui Tae KIM ; Jun Won MIN ; Myung Chul CHANG
Journal of Breast Disease 2018;6(2):35-38
PURPOSE: The eighth American Joint Committee on Cancer staging system for breast cancer was recently published to more accurately predict the prognosis by adding biomarkers such as estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2. However, this system is very complicated and difficult to use by clinicians. The authors developed a program to aid in setting up the staging system and confirmed its usefulness by applying it to theoretical combinations and actual clinical data. METHODS: The program was developed using the Microsoft Excel Macro. It was used for the anatomic, clinical and pathological prognostic staging of 588 theoretical combinations. The stages were also calculated the stages using 840 patients with breast cancer without carcinoma in situ or distant metastasis who did not undergo preoperative chemotherapy. RESULTS: The anatomic, clinical and pathological prognostic stages were identical in 240 out of 588 theoretical combinations. In the actual patients' data, stages IB and IIIB were more frequent in clinical and pathological prognostic stages than in the anatomic stage. The anatomic stage was similar to the clinical prognostic stage in 58.2% and to the pathological prognostic stage in 61.9% of patients. Oncotype DX changed the pathological prognostic stage in 2.1% of patients. CONCLUSION: We developed a program for the new American Joint Committee on Cancer staging system that will be useful for clinical prognostic prediction and large survival data analysis.
Biomarkers
;
Breast Neoplasms*
;
Breast*
;
Carcinoma in Situ
;
Drug Therapy
;
Humans
;
Joints*
;
Neoplasm Metastasis
;
Neoplasm Staging
;
Prognosis
;
Receptor, Epidermal Growth Factor
;
Receptors, Estrogen
;
Receptors, Progesterone
;
Statistics as Topic
8.Iatrogenic Arteriovenous Fistula after Ultrasonography-Guided Core Needle Biopsy for Breast Lesion.
Heeseung PARK ; Seong Hwan BAE ; Jin You KIM ; Taewoo KANG
Journal of Breast Disease 2018;6(1):29-33
Ultrasonography-guided core needle biopsy has been standard of care for diagnosing suspicious breast lesion. The procedure is safe and has a low rate of complications. Most common complication might be bleeding or hematoma, which could be avoided by careful process or changing it to excisional biopsy or managed by proper management. Rarely, Post-procedural arteriovenous fistula is reported in almost all body fields, which is life quality threatening, not life-threatening. Most of them occur with obvious vessel injury, and their primary end-point of management is the obliteration of fistula by thrombosis. However, we experienced a case of iatrogenic arteriovenous fistula after core needle biopsy for breast lesion with small vessel injury which was not but small ones, and its thrill did not disappear even after thrombosis. We would like to share our clinical learnings from surgical management process of this rare complication.
Arteriovenous Fistula*
;
Biopsy
;
Biopsy, Large-Core Needle*
;
Breast*
;
Fistula
;
Hematoma
;
Hemorrhage
;
Iatrogenic Disease
;
Quality of Life
;
Standard of Care
;
Thrombosis
9.A Case of Scalp Metastasis from Breast Cancer without Other Distant Metastases.
Hyunjoo YOO ; Sang Uk PARK ; Jun Yong LEE ; Jiyoung KIM ; Se Jeong OH
Journal of Breast Disease 2018;6(1):25-28
Cutaneous metastases of malignant tumors are relatively rare, and breast cancer is the most common malignancy in women with cutaneous metastases. Since newly developed cutaneous lesions can be the first signs of metastases in breast cancer patients, it is crucial to rule out the possibility of malignancy. Although only a few cases have been reported, breast cancer contributes to a large portion of scalp metastases. This case report demonstrates a rare case of breast cancer metastasis only confined to the scalp. The patient was a 55-year-old woman who was diagnosed with scalp metastasis from breast cancer 10 years after the first curative surgery. The scalp lesion was palpable for 4 years and showed a sudden increase in size over a few months. The patient underwent wide excision with flap coverage. After surgery the patient received radiotherapy, but she has refused additional hormonal therapy. To date, there is no evidence of disease recurrence.
Breast Neoplasms*
;
Breast*
;
Female
;
Humans
;
Middle Aged
;
Neoplasm Metastasis*
;
Radiotherapy
;
Recurrence
;
Scalp Dermatoses
;
Scalp*
10.Clinical Significance of Non-Mass-Like Enhancement of Preoperative Magnetic Resonance Imaging in Breast Cancer Considering Breast-Conserving Surgery.
Min Ji PARK ; Min Young PARK ; Jin Ok KWON ; Kyoung Sik PARK ; Yeong Beom YU ; Jung Hyun YANG ; Soo Min JUNG
Journal of Breast Disease 2018;6(1):20-24
PURPOSE: The purpose of this study was to investigate the significance of non-mass enhancement (NME) findings on preoperative breast magnetic resonance imaging (MRI) when invasive breast cancer patients with single lesions underwent breast-conserving surgery (BCS). METHODS: We reviewed the preoperative MRI findings of 252 patients who underwent BCS from January 2014 to September 2016. Based on the MRI findings, we divided the patients into two groups, those who did and did not have NME, and we retrospectively analyzed the clinical outcomes of the two groups. RESULTS: The NME group had 57 patients, and the no-NME group had 195 patients. The incidence of in situ lesions was higher in the NME group than in the no-NME group (p<0.001). Additionally, the positive resection margin rate on frozen biopsy was higher in the NME group than in the no-NME group (p=0.002). CONCLUSION: When preoperative MRI had NME findings, in situ lesions were more likely to accompany invasive breast cancer lesions, and the positive resection margin rate for frozen biopsy during BCS was high. Therefore, in these cases, the lesion should be excised more widely when BCS is performed, or frozen biopsy for resection margin during BCS should be performed if possible.
Biopsy
;
Breast Neoplasms*
;
Breast*
;
Humans
;
Incidence
;
Magnetic Resonance Imaging*
;
Mastectomy, Segmental*
;
Retrospective Studies